Verve Therapeutics (NASDAQ:VERVE) has appointed Troy Lister, Ph.D., as CSO, effective June 21, 2024, succeeding Andrew Bellinger, M.D., Ph.D., who will serve in an advisory capacity.
Currently, Dr. Lister serves as Verve’s senior vice president of research and early development and brings more than 15 years of biopharmaceutical industry experience specifically in drug discovery, research and development, and program and portfolio leadership to the CSO position.
“In his new role as chief scientific officer, Troy will lead our research efforts as we further advance our pipeline programs, all of which address a robust set of validated cardiovascular targets in areas of high unmet need,” Sekar Kathiresan, M.D., co-founder and CEO of Verve Therapeutics said in a statement.
Prior to joining Verve Therapeutics, Dr. Lister held the role of senior vice president of research and development at Spero Therapeutics where he collaborated in building the research and development organization and led multiple programs into first-in-human studies and through early clinical development.
